Effective treatment of respiratory alphaherpesvirus infection using RNA interference

PLoS ONE

Volumn 4, Issue 1, 2009, Pages

  Fulton, Amy ^a   Peters, Sarah T ^a   Perkins, Gillian A ^a   Jarosinski, Keith W ^a   Damiani, Armando ^a   Brosnahan, Margaret ^a   Buckles, Elizabeth L ^a   Osterrieder, Nikolaus ^a,b   Van de Walle, Gerlinde R ^a  

^a Department of Obstetrics Gynecology   (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN B; HELICASE; ORI HELICASE; ORIGIN BINDING PROTEIN HELICASE; SIGB3; SIGORI2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; DNA BINDING PROTEIN; GLYCOPROTEIN B, SIMPLEXVIRUS; ORIGIN BINDING PROTEINS, VIRAL; ORIGIN-BINDING PROTEINS, VIRAL; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL SPREADING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SYNTHESIS; EQUINE HERPES VIRUS; GENE EXPRESSION; GENE SILENCING; HERPES VIRUS INFECTION; LUNG INFECTION; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RNA INTERFERENCE; RNA SEQUENCE; VIRUS LOAD; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; ANIMAL DISEASE; BAGG ALBINO MOUSE; DISEASE MODEL; GENETICS; HORSE; HORSE DISEASE; IMMUNOLOGY; INFLAMMATION; INTRANASAL DRUG ADMINISTRATION; RESPIRATORY TRACT INFECTION; VIROLOGY;

ALPHAHERPESVIRINAE; EQUID HERPESVIRUS 1; EQUIDAE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, EQUID; HORSE DISEASES; HORSES; INFLAMMATION; MICE; MICE, INBRED BALB C; RESPIRATORY TRACT INFECTIONS; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 58149463225     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004118     Document Type: Article

References (46)

1. Pellett PaRB (2007) Herpesviridae. 5th edition, Fields Virology. Philadelphia: Lippincott, Wilkinson and Wilkins. pp 2479-2499.
2. Allen GP, Bryans JT (1986) Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections. Prog Vet Microbiol Immunol 2: 78-144.
3. Gibson JS, Slater JD, Awan AR, Field HJ (1992) Pathogenesis of equine herpesvirus-1 in specific pathogen-free foals: primary and secondary infections and reactivation. Arch Virol 123: 351-66.
4. USDA-APHIS. Equine herpesvirus myeloencephalopathy: A potential emerging disease. 2007. Internet Communication.
5. Kydd JH, Townsend HG, Hannant D (2006) The equine immune response to equine herpesvirus-1: the virus and its vaccines. Vet Immunol Immunopathol 111: 15-30.
6. Goodman LB, Wagner B, Flaminio MJ, Sussman KH, Metzger SM, et al. (2006) Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1). Vaccine 24: 3636-45.
7. Henninger RW, Reed SM, Saville WJ, Allen GP, Hass GF, et al. (2007) Outbreak of neurologic disease caused by equine herpesvirus-1 at a university equestrian center. J Vet Intern Med 21: 157-65.
8. Garre B, Shebany K, Gryspeerdt A, Baert K, van der Meulen K, et al. (2007) Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. Antimicrob Agents Chemother 51: 4308-14.
9. Garre B, van der Meulen K, Nugent J, Neyts J, Croubels S, et al. (2007) In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet. Vet Microbiol 2007 122: 43-51.
10. Garre B, Gryspeerdt A, Croubels S, De Backer P, Nauwynck H (2008) Evaluation of orally adminstered valacyclovir in experimentally EHV1-infected ponies. Vet.Microbiol; doi:10.1016/j.tvjl.2008.03.027.
11. Dykxhoorn DM, Lieberman J (2006) Knocking down disease with siRNAs. Cell 126: 231-5.
12. Dykxhoorn DM, Lieberman J (2006) Silencing viral infection. PLoS Med 3: e242.
13. Zhang J, Wu YO, Xiao L, Li K, Chen LL, et al. (2007) Therapeutic potential of RNA interference against cellular targets of HIV infection. Mol Biotechnol 37: 225-36.
14. Scherer L, Rossi JJ, Weinberg MS (2007) Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther 14: 1057-64.
15. Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, et al. (2006) An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439: 89-94.
16. Li BJ, Tang Q, Cheng D, Qin C, Xie FY, et al. (2005) Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 11: 944-51.
17. Bitko V, Musiyenko A, Shulyayeva O, Barik S (2005) Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 11: 50-5.
18. Neubauer A, Braun B, Brandmuller C, Kaaden OR, Osterrieder N (1997) Analysis of the contributions of the equine herpesvirus 1 glycoprotein gB homolog to virus entry and direct cell-to-cell spread. Virology 227: 281-94.
19. Martin DW, Deb S (1994) Cloning and expression of an equine herpesvirus 1 origin-binding protein. J Virol 68: 3674-81.
20. Martin DW, Munoz RM, Oliver D, Subler MA, Deb S (1994) Analysis of the DNA-binding domain of the HSV-1 origin-binding protein. Virology 198: 71-80.
21. Hutvagner G, Simard MJ, Mello CC, Zamore PD (2004) Sequence-specific inhibition of small RNA function. PLoS Biol 2: e98.
22. Awan AR, Chong YC, Field HJ (1990) The pathogenesis of equine herpesvirus type 1 in the mouse: a new model for studying host responses to the infection. J Gen Virol 71: 1131-40.
23. van Woensel PA, Goovaerts D, Markx D, Visser N (1995) A mouse model for testing the pathogenicity of equine herpes virus-1 strains. J Virol Methods 54: 39-49.
24. Colle CF III, Tarbet EB, Grafton WD, Jennings SR, O'Callaghan DJ (1996) Equine herpesvirus-1 strain KyA, a candidate vaccine strain, reduces viral titers in mice challenged with a pathogenic strain, RacL. Virus Res 43: 111-24.
25. Ruitenberg KM, Walker C, Wellington JE, Love DN, Whalley JM (1999) Potential of DNA-mediated vaccination for equine herpesvirus 1. Vet Microbiol 68: 35-48.
26. Ruitenberg KM, Walker C, Wellington JE, Love DN, Whalley JM (1999) DNA-mediated immunization with glycoprotein D of equine herpesvirus 1 (EHV-1) in a murine model of EHV-1 respiratory infection. Vaccine 17: 237-44.
27. Frampton AR Jr, Smith PM, Zhang Y, Matsumura T, Osterrieder N, et al. (2002) Contribution of gene products encoded within the unique short segment of equine herpesvirus 1 to virulence in a murine model. Virus Res 90: 287-301.
28. Galosi CM, Barbeito CG, Vila Roza MV, Cid dlP V, Ayala MA, et al. (2004) Argentine strain of equine herpesvirus 1 isolated from an aborted foetus shows low virulence in mouse respiratory and abortion models. Vet Microbiol 103: 1-12.
29. Tsujimura K, Yamanaka T, Kondo T, Fukushi H, Matsumura T (2006) Pathogenicity and immunogenicity of equine herpesvirus type 1 mutants defective in either gI or gE gene in murine and hamster models. J Vet Med Sci 68: 1029-38.
30. von Einem J, Smith PM, Van de Walle GR, O'Callaghan DJ, Osterrieder N (2007) In vitro and in vivo characterization of equine herpesvirus type 1 (EHV-1) mutants devoid of the viral chemokine-binding glycoprotein G (gG). Virology 362: 151-62.
31. Van de Walle GR, Sakamoto K, Osterrieder N (2008) CCL3 and viral chemokine-binding protein gG modulate pulmonary inflammation and virus replication during equine herpesvirus type 1 (EHV-1) infection. J Virol 82: 1714-1722.
32. Van de Walle GR, May ML, Sukhumavasi W, von Einem J, Osterrieder N (2007) Herpesvirus chemokine-binding glycoprotein G (gG) efficiently inhibits neutrophil chemotaxis in vitro and in vivo. J Immunol 179: 4161-9.
33. Barik S, Bitko V (2006) Prospects of RNA interference therapy in respiratory viral diseases: update 2006. Expert Opin Biol Ther 6: 1151-60.
34. Bitko V, Barik S (2007) Intranasal antisense therapy: preclinical models with a clinical future? Curr Opin Mol Ther 9: 119-25.
35. Bitko V, Barik S (2001) Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol 1: 34.
36. Zheng BJ, Guan Y, Tang Q, Du C, Xie FY, et al. (2004) Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. Antivir Ther 9: 365-74.
37. Massaro D, Massaro GD, Clerch LB (2004) Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. Am J Physiol Lung Cell Mol Physiol 287: 1066-1070.
38. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B (2003) Human immunodeficiency virus type 1 escape from RNA interference. J Virol 77: 11531-5.
39. Wilson JA, Richardson CD (2005) Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J Virol 79: 7050-8.
40. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR (2003) Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5: 834-9.
41. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, et al. (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457-62.
42. Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME (2004) Lack of interferon response in animals to naked siRNAs. Nat Biotechnol 22: 1579-82.
43. Dallas A, Vlassov AV (2006) RNAi: a novel antisense technology and its therapeutic potential. Med Sci Monit 12: 67-74.
44. Goodman LB, Loregian A, Perkins GA, Nugent J, Buckles EL, et al. (2007) A point mutation in a herpesvirus polymerase determines neuropathogenicity. PLoS Pathog 3: e160.
45. Allen GP, Yeargan MR (1987) Use of lambda gt11 and monoclonal antibodies to map the genes for the six major glycoproteins of equine herpesvirus 1. J Virol 61: 2454-61.
46. Jarosinski KW, Schat KA (2007) Multiple alternative splicing to exons II and III of viral interleukin-8 (vIL-8) in the Marek's disease virus genome: the importance of vIL-8 exon I. Virus Genes 34: 9-22.